1. Scrip

Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down

 
• By Eleanor Malone

While other large biopharma companies are withdrawing from CNS research, Biogen is rare in not only staying in, but doubling down. Executives at the company’s 40th anniversary event in Switzerland explained why.

Unrecognizable male scientist is plugging a microscopy app into a brain study interface. Science concept for biosciences, molecular engineering, bioengineering, pharmacogenomics, pharmacogenetics.
Biogen sees rapid progress in many aspects of CNS R&D • Source: Shutterstock

“What’s happening in neuroscience right now is like nothing we’ve seen before. Neuroscience is at an inflection point. We have seen the signs and Biogen has chosen to step forward and lead.” Michael Ehlers, Biogen Inc.’s executive vice president, R&D, is convinced that the company is in the right place at the right time, but Biogen’s attitude is unusual.

In recent years, other companies – GlaxoSmithKline PLC, Pfizer Inc., AstraZeneca PLC, Novartis AG, Sanofi among them – have chosen to exit or scale back...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip